Back to Search
Start Over
Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy
- Source :
-
Vaccine . Apr2010, Vol. 28 Issue 18, p3086-3094. 9p. - Publication Year :
- 2010
-
Abstract
- Abstract: Fijian infants aged 6 weeks were stratified by ethnicity and randomized to receive 0, 1, 2, or 3 PCV-7 doses with or without the 23-valent pneumococcal polysaccharide vaccine (PPV-23) at 12 months. Strong booster effects for all 7 PCV-7 serotypes were elicited, and for 4/7 serotypes these responses were highest in the single PCV-7 group. There were fourfold rises in GMC for all non-PCV-7 serotypes. By 17 months the PPV-23 group still had significantly higher GMC (each p <0.001) for all serotypes. The PPV-23 was well tolerated and induced excellent responses for all serotypes which were greatest in the single PCV-7 group. [Copyright &y& Elsevier]
Details
- Language :
- English
- ISSN :
- 0264410X
- Volume :
- 28
- Issue :
- 18
- Database :
- Academic Search Index
- Journal :
- Vaccine
- Publication Type :
- Academic Journal
- Accession number :
- 48893706
- Full Text :
- https://doi.org/10.1016/j.vaccine.2010.02.065